Jakavi 5 Mg. 10 Mg. 15 Mg. 20 Mg 5 mg. 10 mg. 15 mg and 20 mg Tablet.
PDF Leaflet Revision Date: 31 October 2020
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of myelofibrosis and polycythaemia vera.
Dosage (summary)
Starting dose: 15 mg twice daily for MF; 10 mg twice daily for PV.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- Strong CYP3A4 inhibitors
- Dual CYP2C9 and CYP3A4 inhibitors
Contraindications
- Hypersensitivity
- Pregnancy
- Acute infections
- Severe hepatic impairment
- Severe renal impairment
- Active tuberculosis
Common side effects
- Thrombocytopenia
- Anaemia
- Dizziness
- Headache
Counselling Points
- Monitor blood counts regularly.
- Avoid live vaccines.
- Report signs of infection immediately.
Serious warnings
- Risk of serious infections
- Myelosuppression
- Progressive multifocal leukoencephalopathy
Important Disclaimer
The Jakavi 5 Mg. 10 Mg. 15 Mg. 20 Mg 5 mg. 10 mg. 15 mg and 20 mg Tablet. professional information leaflet below is the property of Novartis South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
